Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: BW who wrote (9060)	8/29/2002 2:13:55 PM
From: Bucky Katt	Read Replies (1) \| Respond to of 48461

RE: PHAR The FDA approval they earned today has to do with rapid, point of care tests.... Hmmm, what super-duper ratdog is working on rapid, point of care/exposure tests? There is usually a common theme to stocks I play... Is NETE a buy here? I'll take the 88, 24, 22 & 8 cars anyday... Here is some of the PHAR news> The ENOX Test, PharmaNetics' first theranostic test to be launched, is currently the subject of an expanded clinical trial, ELECT (EvaLuating Enoxaparin Clotting Times). The trial is designed to investigate the clinical relevance of "enoxaparin clotting times" in order to assist physicians in customizing appropriate therapy and facilitating treatment of patient populations including UA/NQWMI patients who transition to percutaneous coronary interventions. The Company expects to enroll 600 patients at 17 medical centers under the direction of its principal investigator, Dr. David Moliterno, Associate Professor of Medicine at The Cleveland Clinic Foundation. Commenting on the news, Dr. Moliterno said, "It is great to finally have a quick reliable method for detecting the extent of anticoagulation provided by enoxaparin. This should help bridge the gap between upstream anticoagulation for unstable angina and procedural anticoagulation during percutaneous coronary interventions." Dr. Jimmy Tcheng co-investigator and Associate Professor of Medicine, Duke University Medical Center, added, "Despite a wealth of positive clinical trials data, the physician community has been reticent to switch from unfractionated heparin to enoxaparin because of the inability to monitor the effects of enoxaparin. I believe that the ENOX Test will produce a paradigm shift in the treatment of coronary artery disease. The ENOX Test, the first device that can rapidly detect the effects of enoxaparin at the point of care, provides that last missing link to better patient outcomes."

To: BW who wrote (9060)	11/10/2002 6:24:32 PM
From: Bucky Katt	Read Replies (1) \| Respond to of 48461

Going back to our NASCAR talk, a little tidbit on todays winner. He is from a tiny little town close to Lake Geneva. mattkenseth.com He raced at Lake Geneva Raceway once or twice, which also has a motocross track, and is where I too raced (motocross) when I was a kid... lakegenevaraceway.com lakegenevamx.com

To: BW who wrote (9060)	2/15/2004 12:56:15 PM
From: Bucky Katt	Read Replies (3) \| Respond to of 48461

Hey BW and the rest of the NASCAR fans here, what do you think of the comments made by Jimmy Spencer regarding Toyota's entry into the truck series? They "bombed Pearl Harbor, don't forget," the San Antonio Express-News quoted the 46-year-old driver as saying during media day at Texas Motor Speedway charlotte.com Is he nuts like the few nuts on this thread? Also, since it is now the NEXTEL cup, and today is the daddy of them all, the Daytona 500, I am reminded on a constant basis how I shorted NXTL into it's all time low, and then was too blind to see the upside potential to go long from the $2.75 area.. I did learn from this though, but it was costly.... Forget what I think I know and follow the technicals...